article thumbnail

Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery

European Journal of Heart Failure

These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions – including drug doses and reasons for non-use, and cause-specific outcomes.

article thumbnail

Heart failure with preserved ejection fraction and atrial fibrillation: clinical management in the context of recent therapeutic advances in heart failure and electrophysiology

Frontiers in Cardiovascular Medicine

Both conditions carry overlapping symptomatology, and delineating between AF and HFpEF from a diagnostic standpoint is challenging as echocardiographic and biomarker assessments used to diagnose HFpEF may be impacted by AF.

article thumbnail

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association

BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. Journal of the American Heart Association, Ahead of Print. mL/kg per minute) in patients with oHCM.

article thumbnail

Cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection

Open Heart

At baseline, low LVEF was associated with persistent CMR abnormality, abnormal GLS associated with low quality of life and abnormal T1 in at least three segments was associated with better clinical outcomes at 12 months. Cardiac-related blood biomarkers could not identify CMR abnormalities in Long COVID.

article thumbnail

Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial

Circulation

Secondary outcomes included daily step count and minutes of moderate-to-vigorous physical activity (MVPA) as measured by the hip-worn Actigraph wGT3X-BT accelerometer, NT-proBNP and hsCRP biomarkers, ejection fraction, anthropometric measures, depression score, self-efficacy, quality of life, and survival risk score. female; 90.6%

article thumbnail

Top 10 Cardiac Diagnosis Trends in 2024

GEMMS

Innovative algorithms analyze gene biomarkers to provide predictive insights and personalized patient therapy. Point of Care Tests Point-of-care testing (POCT) quickly assesses cardiac biomarkers and other heart health indicators, aiding in prompt diagnosis and treatment decisions.

article thumbnail

New Drug Fails to Improve Diabetes-Related Heart Failure

DAIC

Although they had no symptoms of heart failure or blockages in arteries carrying blood to the heart, they all had structural heart disease or abnormal cardiac biomarkers that classified them as having “pre-heart failure,” putting them at high risk for developing overt symptoms of the diagnosis.